p38 MAPK has been implicated in the response to cancer therapy. To determine whether the activation of p38 MAPK could be specific to cancer therapy, we investigated the activation of p38 MAPK in response to several chemotherapeutic agents, such as cisplatin, doxorubicin and taxol in several human cell lines. Activation of p38 MAPK was measured after exposure to several chemotherapeutic agents, using specific phosphoantibodies. Only cisplatin was able to activate p38 MAPK in all the cell lines tested. Furthermore, other platinum compounds such as transplatin and platinum (IV) chloride can induce activation of p38 MAPK. The kinetics of this activation is a key event in the biological role of p38 MAPK in response to cisplatin, as we conclude from the differences observed after treatment with transplatin and cisplatin. The p38 MAPK activation is independent of the origin or genetic alterations of the cell lines and seems to be mediated through both upstream activators MKK6 and MKK3. Although the isoforms a/b are mainly activated, we also demonstrated that other members of the p38 MAPK family were susceptible to activation by cisplatin when they were overexpressed in 293 T. Finally, pretreatment with specific inhibitors (SB 203580 and SKF 86002) induces a resistant phenotype in response to cisplatin. Furthermore, low activation of this SAPK pathway correlates with a resistant phenotype as demonstrated in our experimental model of head and neck cancer. Therefore, we conclude that the p38 MAPK pathway is a specific target for cisplatin-based therapy with clinical implications.
Introduction
Although the signalling events induced by chemo and radiotherapy are one of the most active fields in cancer research, it is still not fully understood how the cells respond to cancer therapy. It is very well established that proteins like Abl (Kharbanda et al., 1998) , DNA-PK (Smith and Jackson, 1999) , ATM (Khanna and Jackson, 2001 ) and p53 (Lakin and Jackson, 1999) are implicated in the response to chemo-and radiotherapy. Most of these proteins have been linked to the stressactivated protein kinase family (SAPK), as their activators (Kharbanda et al., 1995; Pandey et al., 1996; Yu et al., 2000) . The c-Jun N-terminal kinase (JNK) and the p38 mitogen-activated protein kinase (MAPK) mainly comprise the SAPK family. In the case of JNK, its role in cancer therapy is very well established (Sanchez-Perez et al., 1998; Verheij et al., 1998) . p38 MAPK has been implicated in inflammation, osmotic stress, cell cycle regulation, differentiation and many other biological processes (for a review, see Nebreda and Porras, 2000; Kyriakis and Avruch, 2001 ). However, the implication of p38 MAPK in cancer therapy is not clear. Recently, a growing body of evidence suggests that p38 MAPK is able to control the p53-mediated response to several genotoxic stimuli, such as UV light and cisplatin (CDDP) (Bulavin et al., 1999; Sanchez-Prieto et al., 2000) . Indeed, c-Abl has been shown to control p38 MAPK activation after CDDP exposure (Pandey et al., 1996) and also the activation seems to be mediated by ASK1 (Chen et al., 1999) . However, most of these studies have been performed using experimental models such as NIH 3T3 or 293 cells and no comparison with other antitumour treatments has been carried out so far. Furthermore, no study has been performed with nontransformed human cell lines, which indicates that there is still no definitive clue about the role of p38 MAPK in response to chemo or radiotherapy.
Among the several antitumour drugs, some of the most representative and better characterized are CDDP, doxorubicin (DOX) and taxol (TAX). CDDP is a typical DNA-damaging agent with the ability to induce crosslinking between inter and intra DNA strands (Trimmer and Essigmann, 1999) . CDDP is known for its ability to induce apoptosis, although it is not the only way to induce cell death (for a review see Gonzalez et al., 2001) . CDDP is used in several types of tumours such as head and neck, ovary or lung cancer. DOX, an antitumour antibiotic used in several tumours, has been demonstrated to be a potent intercalating agent with the ability to induce the production of free radicals that generate single and double-strand breaks and also to block DNA modifying enzymes, such as topoisomerases and helicases (Cummings and Smyth, 1993) . TAX belongs to a family of drugs that are able to interfere with the normal progression of the cell cycle by blocking microtubule formation, and has been successfully used in breast and ovary tumours (Blagosklonny and Fojo, 1999; Hortobagyi, 1999) . Finally, g radiation is a physical agent, which also generates free radicals, and its major target is the DNA molecule, inducing mainly double-strand breaks.
In order to establish the role of p38 MAPK in cancer therapy, we decided to investigate the activation upon several antitumour treatments. Our data indicate a determinant role for p38 MAPK in CDDP-based cancer therapy.
Results

p38 MAPK is preferentially activated by CDDP
In order to test the specificity of p38 MAPK activation for cancer therapy, we decided to test several drugs (CDDP, DOX and TAX) in a number of human cell lines like IMR90, HaCaT, Hela, A431, HN30 and HN19, and also in 293 T and Cos7, cell lines widely used for signal transduction studies. Cells were treated for up to 6 h with 66 mm CDDP, 1.7 mm DOX or 100 nm TAX. As shown in Fig 1a, CDDP produced the strongest activation of p38 MAPK in all the cell lines tested. This induction was independent of the cell line and we were able to detect it as early as 1 h (data not shown), indicating the specificity in the p38 MAPK activation. In the case of DOX, we were able to detect a clear increase in p38 MAPK phosphorylation in Hela and 293 T cells, while in HaCaT, IMR90, A431, and HN19 cells we detected a slight activation and in other cell lines like HN30 or Cos we did not detect a clear activation. This suggests cell-type specificity in the role of p38 MAPK activation in the response to DOX. Finally, in the case of TAX, in general no clear activation was detected, especially when compared to CDDP, although in HaCaT and Cos7 cells we were able to detect a low activation at 6 h. As a loading control, all the membranes were reprobed against a p38 MAPK antibody. No variation in the total amount of p38 MAPK was detected.
In order to establish a correlation between p38 activation and the toxicity of these compounds, we decided to test the effects of all the drugs in a viability assay for 24 h in HaCaT cells, a model in which p38 MAPK was activated clearly by CDDP and poorly by TAX and DOX (Figure 1a) . No clear differences were seen among the drugs in terms of viability except for TAX (Figure 1b) . Therefore, we used a 10-fold increase in the dose, rendering almost the same toxicity, suggesting that we are working in the maximum toxicity for TAX (Figure 1b) . Anyway, we cannot establish a correlation between drugs and p38 MAPK activation based on the toxicity.
Furthermore, we decided to check other MAPK pathways to see if p38 MAPK was activated because of a general stress situation in the cell. As it has been previously described that JNK and ERK1/2 are implicated in the cellular response to CDDP (Cui et al., 2000; Wang et al., 2000a) , we performed a doseresponse assay for CDDP, ranging from 33 to 132 mm (Figure 1c) , at 4 h. While the first dose (33 mm) was able to activate the SAPK pathway (JNK and p38 MAPK), no activation of ERK1/2 was detected at these early time points. These data support a clear specificity for the JNK and p38 MAPK pathways in the response to CDDP, at least in the early time points in our model of HaCaT cells.
Transplatin and Cl 4 Pt, but not g radiation, are able to induce a transitory activation of p38 MAPK In order to gain further insight into the molecular mechanism of p38 MAPK activation by CDDP, we decided to investigate if the early activation was because of the toxicity. Following this idea, we took advantage of transplatin (TDDP), a derivate of CDDP, with some of the biological properties of CDDP but with no toxic effects and no clinical use (Boudvillain et al., 1995) . HaCaT cells were treated as previously described and p38 MAPK activation was measured at different times. We detected a clear activation after 1 h in the presence of TDDP (66 mm), but this activation was abolished after 6 h. Activation of the p38 MAPK induced by CDDP followed the same kinetics but was maintained up to 9 h and more ( Figure 2a and data not shown). As expected in terms of viability by crystal violet, no effect was observed by TDDP, while CDDP-associated toxicity was close to 100% after 24 h (Figure 2a) . Similar results were obtained in 293 T cells (data not shown). This result indicates that the early activation of p38 MAPK (up to 3 h) is not related to the toxicity, but a stable activation correlates with the toxicity induced by CDDP. Furthermore, we used Cl 4 Pt (66 mm during 4 h), obtaining similar results to TDDP in terms of p38 MAPK activity and viability (Figure 2b ). These results indicate that p38 MAPK activation is due, at least in part, to the presence of platinum or some of the biological properties shared between Cl 4 Pt, TDDP and CDDP, and also that the kinetics seem to be related to the toxicity mediated by CDDP.
To check if other DNA-damaging agents were able to activate p38 MAPK, HaCat and 293 T cells were irradiated with a lethal dose of g radiation (20 Gy); no clear early or late activation was detected in HaCaT or 293 T cells ( Figure 2c and data not shown), supporting the specificity of p38 MAPK for platinum compounds in our experimental model of HaCaT cells. Taking into account the activation induced by TDDP, Cl 4 Pt or CDDP, some type of damage associated with the presence of these platinum compounds is able to trigger early p38 MAPK activation, while the toxicity only correlates for a sustained activation of p38 MAPK.
p38 MAPK activation is mediated by MKK3 and MKK6
The p38 MAPK pathway has two main upstream activators: MAPK kinase (MKK) 3 and 6. Recent evidence suggests that MKK6 is the main upstream activator in response to CDDP, mediated through c-Abl kinase. We took advantage of the availability of specific antibodies that recognize activated forms of MKK6 and MKK3, and decided to investigate which pathway was activated in HaCaT cells by CDDP. Total cell lysates were probed against phospho-MKK6/3 and a clear band was detected after treatment with CDDP ( Figure 3a ). To elucidate which pathway is activated, we performed immunoprecipitation against MKK3. A clear activation of MKK3 was detected, suggesting that one of the main upstream activators is MKK3 (Figure 3a ). To investigate if this observation was a mechanism specific for HaCaT cells, we decided to evaluate endogenous MKK3 in other cell systems such as 293 T or Cos cells. We were able to detect a clear activation in both cell lines (Figure 3b ). To demonstrate the activation of both upstream activators, wild-type forms of HA tag MKK6 or MKK3 were transfected in 293 T cells. Once transfected, cells were treated with CDDP (66 mm) for 4 h, and phosphorylation of MKK6/3 was measured. Clearly, the transfected MKK3 and Figure 1 p38 MAPK is preferentially activated by CDDP. (a). Several cell lines (subconfluent cultures) were treated with CDDP (33 mm), DOX (1.7 mm) and TAX (100 nm) for 3 and 6 h. Total cell lysates (50 mg) were resolved by SDS-PAGE and immunoblotted with anti-P-p38 MAPK and p38 MAPK. In all the cases, a clear activation of p38 MAPK was detected with CDDP. (b) Viability to different chemotherapeutic agents was evaluated in HaCaT cells for 24 h. No significant differences were detected between CDDP and DOX. TAX induces a toxicity close to 80% that was not increased by a 10-fold increase in the dose. This is the average of three independent experiments performed in triplicate culture. Bars mean s.d. (c). HaCaT cells were treated for 4 h with several doses of CDDP and ERK1/2, JNK and p38 MAPK activity was assayed using specific phosphoantibodies. No significant activation of ERK1/2 was detected. The autoradiograms are from a representative experiment that was repeated three times with nearly identical results MKK6 were activated by CDDP (Figure 3c ). Furthermore, HA-p38 MAPK was cotransfected with mutant forms of MKK6 or MKK3 and treated with or without CDDP (66 mm); both inactive kinases were able to block p38 MAPK activation by CDDP (Figure 3d ). These experiments support the fact that both the upstream kinases MKK3 and MKK6 could be activators of p38 MAPK in response to CDDP.
Role of p38 MAPK d in CDDP response
Recently, another member of the p38 MAPK family, p38 MAPK g/ERK6, has been implicated in the response to genotoxic stress mediated by UV, CDDP and g radiation (Pillaire et al., 2000; Wang et al., 2000b) . In order to study the role of the other member of the family, p38 MAPK d/SAPK4, we decided to investigate the expression levels in several cell lines. All the cell lines showed lower levels of expression for p38 MAPK d than p38 MAPK a (Figure 4a ). As a control we used Hela cells, with no expression of p38 MAPK d as has been previously described (Jiang et al., 1997) . Therefore, we decided to see if endogenous p38 MAPK d was activated after CDDP exposure (66 mm). We were able to detect activation of p38 MAPK a/b and also of p38 MAPK g in several experimental systems such as IMR90 (Figure 4b ). To study whether the lack of activation was because of the lower expression of different members, we overexpressed exogenous p38 MAPK d, g and a, all of them tagged with HA, in 293 T cells. After transient transfection, cells were treated with CDDP 66 mm for 4 h. Then, kinases were immunoprecipitated and activation was measured using anti-P-p38 MAPK. We were able to detect a clear activation of p38 MAPK g and d, similar to p38 MAPK a, indicating that all members of the p38 MAPK family are also targets of CDDP (Figure 4c) , and that probably the null activation for p38 MAPK d could be because of the low expression level among other issues.
Inhibition of p38 MAPK activation increases resistance to CDDP
To test the biological role of p38 MAPK in the CDDP response, we used the specific inhibitors of p38 MAPK, SKF86002 and SB 203580. Cells were pretreated with 10 mm of each inhibitor for 1 h and then incubated with CDDP (doses ranging from 1.7 to 6.6 mm) during 48 h. There was an increase in the viability of those HaCaT cells pretreated with p38 MAPK inhibitors, as the doseresponse assay indicates (Figure 5a ). In the case of SB203580, the increase in viability is slightly lower than that for SKF86002. This difference can be explained by the high specificity of SB203580 for isoforms a and b, through binding to the ATP site (Young et al., 1997) , while SKF860002 can block the activation of all p38 MAPK isoforms (Lee et al., 1994; Sodhi et al., 2000; Watanabe et al., 2001) . To evaluate the clinical implications of our previous finding, we decided to assess the role of p38 MAPK in a tumoral model such as head and neck (Patel et al., 1997 (Patel et al., , 1998 , in which the CDDP is a key therapeutic element. Taking advantage of the difference in p38 MAPK behaviour observed between the two head and neck cancer cell lines, HN19 and HN30 (Figure 1a) , we decided to perform a doseresponse assay in terms of p38 MAPK activation and viability. Clearly, HN30 induced a lower activation of p38 MAPK (Figure 5b ) correlating with a resistant phenotype (Figure 5c ). Furthermore, Akt and ERK1/2 pathways were analysed (Figure 5d, e) . No clear activation of Akt or ERK1/2 was observed in HN19 , in 60 mm plates, using lipofectamine. At 24 h after transfection, cells were treated with CDDP (66 mm) for 4 h. Anti-HA immunoprecipitates were immunoblotted against P-MKK3/6, and membranes were reprobed against HA. A clear activation of both p38 MAPK activators was detected. The autoradiograms are from a representative experiment that was repeated three times with nearly identical results. (d) 293 T cells were transiently transfected with pRSV-Flag-MKK3Ala (2 mg) or pCDNA3-Flag-MKK6 (K82A) (2 mg), in 60 mm plates, using lipofectamine. At 24 h after transfection, cells were treated with CDDP (66 mm) for 4 h. Anti-HA immunoprecipitates were immunoblotted against P-p38, and membranes were reprobed against HA. Clearly, expressions of both dominant negative were able to diminish p38 MAPK activation. The autoradiograms are from a representative experiment that was repeated three times with nearly identical results and HN30, supporting the specificity of the different p38 MAPK isoform activations in response to CDDP. However, it is important to mention that higher basal levels of AKT were detected in HN30, supporting previous reports (Brognard et al., 2001 ).
Taken together, these results indicate that inhibition or low activation of the p38 MAPK pathway correlates with a resistant phenotype with potential clinical implications.
Discussion
Recently, the family of SAPK, mainly JNK (Verheij et al., 1998; Sanchez-Perez and Perona, 1999; SanchezPerez et al., 2000) , has been implicated in cancer therapy. As in the case of JNK, the p38 MAPK has also been implicated in genotoxic stress mediated by chemotherapeutic drugs (Cong and Goff, 1999; Sanchez-Prieto et al., 2000) . With the aim of clarifying the role of the p38 MAPK in response to different anticancer agents in several human normal and transformed cell lines, we studied the activation of this signal transduction pathway in response to CDDP, DOX, TAX and g radiation.
The first conclusion is that in all the cell lines tested, in a similar range of toxicity for CDDP, TAX or DOX, CDDP induces a faster and more potent p38 MAPK activation. Indeed, we used short time points in order to gain specificity. It is remarkable that DOX was able to induce p38 MAPK activation in some cell lines such as Hela or 293 T, as has been previously described (Sanchez-Prieto et al., 2000) , and that TAX failed to induce p38 MAPK in most of the cell systems tested. Recently, it has been reported that TAX can be a potent inducer of p38 MAPK in MCF7 breast cancer cell lines (Bacus et al., 2001) , while in oesophageal squamous cancer cell lines this activation is after 48 h (Okano and Rustgi, 2001) , suggesting that this phenomenon is at least cell-type specific as our data support. Nevertheless, p38 MAPK seems to be a universal sensor for CDDP presence and is independent of nontumorigenic status (IMR90), mutations in p53 (HaCaT), expression of oncogenic viral proteins (293 T, Cos, Hela) and tumour type (A431, HN30 and HN19).
We propose that the specificity in the early p38 MAPK activation by CDDP is not because of its genotoxic/antitumour effect, but seems to be mediated by some properties or damages associated probably with the presence of platinum, as indicated by the experiment with the nontoxic derivate TDDP or with Cl 4 Pt. In the case of TDDP and CDDP, there are common properties like some types of adducts to DNA or the possibility to bind certain proteins (Lippert, 1996; Zlatanova et al., 1998) . It is important to note that in addition to Cl 4 Pt, other heavy metals, like cadmium, have proved to be potent activators of p38 MAPK (Galan et al., 2000) , suggesting the possibility that p38 MAPK could be a sensor for heavy metals. However, other compounds such as DOX or g radiation are able to activate p38 MAPK in other experimental systems, indicating that further studies are necessary to clarify the specificity in the p38 MAPK activation in response to platinum compounds. Total cell lysates (100 mg) were immunoblotted using specific antibodies against p38 MAPK d and reprobed against p38 MAPK a and g tubulin as a loading control. All the cell lines express p38 MAPK a and lower levels of d, except Hela cells with no expression of p38 MAPK d. (b) IMR90 cells were treated with 66 or 132 mm of CDDP for 4 h and total cells lysed were blotted against P-p38 MAPK. In short exposure (lower than 2 min) the only band detected was p38 MAPK a/b, but longer exposures allow us to detect a third band corresponding to p38 MAPK g. (c) 293 T cells were transiently transfected with pCEFL-HA-P38 MAPK a (2 mg), pCEFL-HA-P38 MAPK g (2 mg) or pCEFL-HA-P38 MAPK (2 mg), in 60 mm dishes, using lipofectamine. At 24 h after transfection, cells were treated with CDDP (66 mm) for 4 h. Anti-HA immunoprecipitates were immunoblotted against P-p38 MAPK and membranes were reprobed against HA. A clear activation in all the cases was detected. The autoradiograms are from a representative experiment that was repeated three times with nearly identical results
The use of TDDP shows that the kinetics of the activation is a key event in the biological activity of p38 MAPK, as has been proposed for JNK (Sanchez-Perez et al., 1998) . One of the possibilities to explain the different kinetics of CDDP and TDDP are the differences in DNA binding between the two isomers (Kasparkova and Brabec, 1995; Kasparkova et al., 2001) . However, other possibilities, like differences in DNA stability, DNA repair or intrinsic reactivity, should be taken into consideration (Lippert, 1996) . It is clear that DNA damage by itself, represented by a double-strand break induced by g radiation, is not able to induce p38 MAPK activation in our model of HaCaT cells, pointing out again the specificity of the p38 MAPK pathway for CDDP. The biological meaning of stable activation of p38 MAPK could be the activation of downstream targets such as p53 (Bulavin et al., 1999; Sanchez-Prieto et al., 2000; She et al., 2000) or p73 .
The activation of the p38 MAPK pathway is mediated by the upstream kinases MKK6 and MKK3 (Cuenda et al., 1996) . In the case of CDDP, the MKK6 pathway is apparently the main mediator of p38 MAPK activation, as has been previously described in MEF (Cong and Goff, 1999) . Our experiments indicate that endogenous MKK3 is activated by CDDP, at least in HaCaT, 293 T and Cos cells. Furthermore, our transient experiments using WT and kinase death forms support the fact that both MKKs are implicated in the final activation of p38 MAPK by CDDP. These data suggest a new MKK3-dependent pathway that needs to be fully elucidated.
The p38 MAPK family is composed of four members. Among them, a and b seen to be ubiquitous and their role in stress is well established. Recently, it has been reported that p38 MAPKg is activated by CDDP (Pillaire et al., 2000) and also by g radiation (Wang et al., 2000b) . No data are known about p38 MAPK d in terms of genotoxic stress. Our results showed lower levels of p38 MAPK d than p38 MAPKa, and activation /well), 16-24 h prior to treatment with CDDP (doses ranging from 0 to 132 mm). Viability was assayed by the crystal violet method 24 h later. Clearly, HN19 was more sensitive to CDDP than HN30. This is the average of three independent experiments performed in triplicate. Bars mean s.d. (d) HN19 and HN30 cells were treated and processed as in (b) and blotted against P-AKT (Ser 473); no differences were seen between the cell lines. As a positive control, cells were starved for 16 h and treated with insulin (100 nm) for 10 min. As a loading control, total Akt protein was also measured. (e) HN19 and HN30 cells were treated and processed as in (b) and blotted against phospho-ERK1/2; no differences were seen between the cell lines. As a positive control, cells were starved for 16 h and treated with 20% FCS for 10 min. As a loading control, ERK1/2 protein was also measured of endogenous p38 MAPK a and g, but not of p38 MAPK d. However, overexpression of the kinases in 293 T cells led us to detect clear activation by CDDP of all the isoforms. This apparent different regulation could indicate that overexpression assays should be followed by more physiological approaches. These data indicate that the role of p38 MAPK d is probably marginal and needs at least a higher level of expression and probably a stronger signal from upstream activators such as MKK6 (Alonso et al., 2000) . Further studies are necessary to clarify the role of each p38 MAPK family member in the response to CDDP and, in general terms, to genotoxic stress.
From the clinical point of view, it is important to note that in our experimental head and neck cancer model, lower activation or lack of activation of p38 MAPK correlates with a more resistant phenotype, suggesting that the inhibition of p38 MAPK could be a potential mechanism of resistance. Indeed, our data in HaCaT cells with the specific p38 MAPK inhibitors (SB 203580 and SKF86002) support these observations because of the specificity of the dose chosen, 10 mm, with no significant effect on the other related signalling pathways such as ERK or JNK (Davies et al., 2000) . In our experimental model of head and neck cancer cells, no activation of AKT or ERK1/2 by CDDP was detected, suggesting a main role for the p38 MAPK pathway. However, higher levels of phosphorylated AKT were detected in the HN30 cell line. In this sense, it is important to note that recent evidence suggests a role for the AKT/PKB in the cellular response to CDDP (Hayakawa et al., 2000; Mitsuuchi et al., 2000; Asselin et al., 2001) , which interestingly has been linked to the p38 MAPK pathway (Nomura et al., 2001; Rane et al., 2001) . Therefore, we cannot exclude that, because of the crosstalk between signalling pathways, other kinases, such as AKT, can be involved in CDDP resistance as has been reported in lung carcinoma cell lines (Brognard et al., 2001) .
Finally, the implications of this study are clear. First, CDDP, TDDP and Cl 4 Pt are able to trigger the signal that leads to the early activation of p38 MAPK, while other genotoxic stresses are not able to activate in the same fashion. Second, among the several Pt compounds used, only CDDP is able to induce long-term activation of p38 MAPK. CDDP has, as the major target, the DNA molecule. This fact is shared with other antitumour treatments, like g-radiation, but we were unable to detect p38 MAPK activation induced by g radiation. This result indicates that there are other mechanisms triggered by CDDP, and not by g radiation, which lead to the activation of p38 MAPK. Third, both upstream (MKK6/3) and all the members of the p38 MAPK family are activated by CDDP, at least in transient experiments. Fourth, the lack of p38 MAPK activation/ function induces a resistant phenotype in human cells. Therefore, our results support a role for the p38 MAPK pathway in CDDP-based therapy with clear implications in terms of resistance. Further studies are necessary to evaluate the use of p38 MAPK activation as a marker with clinical implications.
Materials and methods
Chemicals and antibodies
Antibodies to phosphorylated forms of JNK, p38 MAPK, AKT, MKK3/6 and ERK1/2 were from Cell Signalling Tech. Antibodies against the nonphosphorylated forms of p38 MAPK, JNK, AKT, SAPK4, ERK6, ERK1/2, MKK3 and HA were from Santa Cruz Biotechnology. Antibody against Flag and g Tubulin was from Sigma. SKF860002 and SB203580 were from Calbiochem. CDDP and TDDP were from Sigma, platinum (IV) chloride (Cl 4 Pt) was from Merck, and DOX (Pharmacia&Upjhon) and TAX were from Bristol Myers. All drugs were prepared immediately before use. Insulin (Actrapid) was from Novo Nordisk.
Cell lines and plasmid 293 T, A431, IMR90, Cos-7, Hela, HaCaT, HN19 and HN30 were maintained in 5% CO 2 , 371C in DMEM (Gibco BRL) supplemented with 10% FCS plus antibiotics (Biowhittaker). HA-p38, HA-ERK6 and HA-SAPK4 in pCEFL have been previously described (Chiariello et al., 2000) . Wild-type forms of MKK6 and MKK3 were kindly supplied by Dr JR Woodgett (Experimental Therapeutics Ontario Cancer Center, Toronto, ON, Canada). Inactive kinase forms of MKK6 and MKK3 were kindly supplied by Dr R Davis (Howard Hughes Medical Institute and Program in Molecular Medicine, University of Massachusetts Medical School, MA, USA).
Western blotting immunoprecipitation assay
Cells were treated and collected in lysis buffer (25 mm HEPES pH 7.5,. 0.3 m NaCl, 1.5 mm MgCl 2 , 0.2 mm EDTA, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid, 20 mm B-glycerophosphate) in the presence of protease and phosphatase inhibitors (2 mg/ml leupeptin, 2 mg/ml aprotinin, 1 mm PMSF and 0.1 mm Na 3 VO 4 ). Then, 50 mg were loaded onto 10% SDS-PAGE and blotted against the different kinases using specific antibodies against the phosphorylated form or against the total protein. In the immunoprecipitation assay, extracts were precleared and soluble fraction was incubated with anti-HA or MKK3 (1 mg/sample). After at least 2 h, extracts were incubated for 45 min in the presence of protein G (gamma Bind Sepharose, Pharmacia Biotech) and then washed three times in the same lysis buffer. Then immunocomplexes were resuspended in loading buffer and loaded onto 10% SDS-PAGE gels. Quantification of autoradiograms was performed by using Scion Image software.
Viability
Viability was evaluated by the crystal violet method (Viniegra et al., 2002) . Colorant was recovered by 1% acetic acid and OD was evaluated at 590 nm. In the case of SKF86002 or SB203580, cells were pretreated for 1 h before treatment.
Transfections 293 T cells were transiently transfected using lipofectamine (Gibco BRL) following the manufacturer's instructions. The total amount of DNA was normalized using empty vector. Cells were treated 24-36 h after transfection and samples were processed. the assistance and advice of Drs Alvarez Vallina, Romero and Klander. This work was supported by Grants FIS (01/04075) and SAF (2001/0376). Javier Herna´ndez Losa is supported by a FIS contract.
